Navigation Links
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results
Date:2/11/2009

ter of 2008 and $0.78 for the fourth quarter of 2007.

OPERATIONAL HIGHLIGHTS

On November 6, 2008, Vanda submitted a Complete Response to the not approvable action letter that the Company received from the U.S. Food and Drug Administration (FDA) on July 25, 2008 regarding iloperidone. The FDA has indicated that it has accepted the Complete Response for review and has set a new target action date of May 6, 2009.

Pending a response from the FDA, Vanda is concentrating its efforts on the design and evaluation of clinical development options for tasimelteon, its compound for sleep and mood disorders. Results of prior phase II and III clinical trials for tasimelteon were published in the December 2008 issue of The Lancet.

On December 16, 2008, Vanda announced a workforce reduction of 17 employees, including two officers.

FINANCIAL DETAILS

  • Operating Expenses. Fourth quarter 2008 R&D expenses, primarily consisting of salaries and related costs of R&D personnel, including $0.6 million of severance expense and the costs of regulatory consultants, totaled $3.6 million, compared to $3.8 million for the third quarter of 2008 and $12.6 million for the fourth quarter of 2007. The decrease in R&D expenses in the fourth quarter of 2008 relative to the third quarter of 2008 is primarily due to the decrease in stock-based compensation expense for R&D personnel due to the cancellation of unvested options in connection with the workforce reduction. The decrease in R&D expenses in the fourth quarter of 2008 relative to the fourth quarter of 2007 is primarily attributable to lower clinical trial costs in the fourth quarter of 2008 compared to the costs from trials conducted in the fourth quarter of 2007. For the full year of 2008, total R&D expenses were $23.9 million, compared to $47.2 million for the full
    '/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
2. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
3. Vanda Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008
4. LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests
5. Vanda Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
6. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Roth Capital Partners 21st Annual OC Growth Stock Conference
8. Sagent Pharmaceuticals Announces Expansion of Cefazolin Product Line to Include Cefazolin for Injection, USP in 500mg Single-Dose Vial
9. PacificGMP and LigoCyte Pharmaceuticals Announce cGMP Manufacturing Collaboration
10. Diffusion Pharmaceuticals Announces Completion of a $2.9 Million Private Placement and Company Presentations at Upcoming Industry Conferences in Geneva, Switzerland and Naples, Florida
11. Tigris Pharmaceuticals Files IND Application for GGTI-2418
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... ON , July 11, 2014 /CNW/ - Sunovion ... approved APTIOM TM (eslicarbazepine acetate) for use as ... seizures in patients with epilepsy who are not satisfactorily ... indicated for use in patients under 18 years of ... most common neurological disorders and according to Epilepsy Canada, ...
(Date:7/10/2014)... 2014 Deep Knowledge Ventures last ... on ‘Commercialising Longevity Research’ and welcomed a host ... London Bioscience Innovation Center for the event, organised ... Analytics Ltd. The meeting highlighted the need for ... for age-related disease, as well as the crucial ...
(Date:7/10/2014)... CA (PRWEB) July 10, 2014 OMICS ... Bioanalytical techniques during 18-20 August, 2014 at Double Tree ... review the recent developments in Analytical & Bioanalytical research ... globe. , Speaking on this occasion, Dr. Srinubabu Gedela, ... Analytica Acta conference is a remarkable one in bringing ...
(Date:7/10/2014)... 2014  Kainos Capital, a firm specializing in acquiring ... it has acquired the Slim-Fast brand from Unilever. Unilever ... of the transaction were not disclosed. Slim-Fast ... that markets ready-to-drink shakes, powders, bars and snacks to ... and in the United Kingdom ...
Breaking Biology Technology:Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Kainos Capital Acquires Slim-Fast From Unilever 2
... Mich., Sept. 23 Sanford Rose Associates®-Rochester, an ... Rose Associates® network of offices, was recently named ... Sanford Rose Associates®-Rochester was established in January 2009 ... professional searches in the automotive, alternative energy, defense, ...
... BEACH, Calif., Sept. 23 Genesis Biopharma, Inc. (OTC Bulletin ... cancer therapies, today announced that it has closed a private ... accredited investors to purchase 933,341 shares of its common stock ... Series A warrants to purchase 466,674 shares at an exercise ...
... Association (BMA) Award Winning Medical Authors and Editors -- LONDON, September 23, 2010 ... ... --> ... s = ,; var first_result; // Results are keyed by longUrl, so we need to grab the ...
Cached Biology Technology:Genesis Biopharma Announces $700K Private Financing 2Elsevier Congratulates its British Medical Association (BMA) Award Winning Medical Authors and Editors 2Elsevier Congratulates its British Medical Association (BMA) Award Winning Medical Authors and Editors 3Elsevier Congratulates its British Medical Association (BMA) Award Winning Medical Authors and Editors 4Elsevier Congratulates its British Medical Association (BMA) Award Winning Medical Authors and Editors 5Elsevier Congratulates its British Medical Association (BMA) Award Winning Medical Authors and Editors 6Elsevier Congratulates its British Medical Association (BMA) Award Winning Medical Authors and Editors 7Elsevier Congratulates its British Medical Association (BMA) Award Winning Medical Authors and Editors 8
(Date:7/11/2014)... from the Max Planck Institute for Medical Research in ... understanding photosynthesis, the process by which the Earth first ... and which is therefore crucial for all higher forms ... the first direct visualization of a crucial event in ... specific protein complex, photosystem II, splits water into hydrogen ...
(Date:7/11/2014)... of kidney injury related to the use of hydroxyethyl ... HES molecules, according to a report in Anesthesia ... Research Society (IARS). , The "total mass of HES ... human renal proximal tubule cells (PTCs), concludes the laboratory ... Hospital Wrzburg, Austria. Other factorssuch as differences in ...
(Date:7/11/2014)... is evidence that under the normal circumstances, ... development, maintain neuronal environment, and exhibit therapeutic ... neurodegenerative disease. Previous studies have found that ... after chemical induction have reduced viability, which ... Prof. Xiaodong Yuan, Kailuan General Hospital, Hebei ...
Breaking Biology News(10 mins):A first direct glimpse of photosynthesis in action 2In lab studies, hydroxyethyl starch has direct harmful effects on kidney cells 2
... Mich. Ask any political leader if they are ... typically a resounding, "Yes." Evaluating its effectiveness, however, ... and environmental science and policy professor at Michigan State ... evaluate sustainability at a national gathering of scientists Feb. ...
... NC How did early humans adapt to different climates and ... the globe? And what does that mean for humans living today? ... and anthropology will present their findings on Sunday February 20th at ... titled "Humans Without Borders: Evolutionary Processes at Work In Humans ...
... At this year,s American Association for the Advancement ... to 21, Caltech researchers will present topics ranging from ... in bioengineering. Caltech,s Alice S. Huang, AAAS president, ... highlighting this year,s AAAS theme, "Science Without Borders." ...
Cached Biology News:It's time to take a unified approach toward measuring sustainability 2Panelists to discuss evolution of human brain size, skin color and diet at AAAS meeting 2Tip sheet: Caltech researchers presenting at AAAS 2Tip sheet: Caltech researchers presenting at AAAS 3
Automated centrifuge for the processing of microplates and tubes; can be integrated into automated process using inexpensive robotics due to its unique sample handling platform....
... is designed for use with HRP conjugated rabbit ... mouse monoclonal coating antibody. • ... prevent non-specific binding between the coating and detection ... may be used to stabilize newly conjugated antibodies, ...
EZ-Tn5™ Transposase is designed for use with our pMOD™ series of vectors as well as any EZ-Tn5™ transposon system....
... PBL's bioassays for interferons are cytopathic effect inhibition ... Sample types include; tissue culture supernatents; serum ... these assays, one unit is defined as the ... the cytopathic effect of viral infection by 50%. ...
Biology Products: